Zentek has announced that its wholly-owned subsidiary Triera Biosciences has received a CAD$1.1 million (around USD$791,000) Government of Canada contract to test its multivalent aptamer technology for the rapid drug discovery of therapeutics or prophylactics of highly pathogenic avian influenza (“HPAI”) A(H5N1).
